Cochlear share price edges lower on successful completion of capital raise

The Cochlear Limited (ASX: COH) share price is edging lower today as the company announced it has successfully raised $880 million in funds.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price has edged slightly lower today as shares resume trading after being placed in a trading halt yesterday. This morning, the healthcare provider announced it has successfully raised $880 million in institutional funds.

$880 million raised in an institutional placement

Cochlear announced today that it has completed its capital raising of $880 million via a fully underwritten institutional placement of approximately 6.3 million new fully paid ordinary shares. Each of these shares is priced at $140 per share, which is a 16% discount from the stock's previous closing price.

Cochlear noted that it had witnessed strong demand for the placement and all the shares were able to be fully allocated to the company's existing institutional shareholders.

The size of the placement was initially set to $800 million on March 25. However, this was later increased to $880 million due to strong demand from both local and global investors.

Cochlear reported yesterday that the coronavirus outbreak is anticipated to cause major disruption to its business. This comes as elective surgeries such as those for Cochlear implants are deferred across a growing number of countries globally, including many European countries and the US.

Current difficulties for the company from the coronavirus crisis have been compounded by Cochlear's recent lost court appeal in the US. The healthcare company was ordered to pay US$268 million in damages to two separate research institutes in the US regarding patent infringements.

Where the new funds will be allocated

Cochlear noted that the new funds will be used to strengthen the company's balance sheet and provide it with additional flexibility from a liquidity perspective in the current uncertain and volatile economic times ahead. Future net debt will also be significantly reduced, and the company now believes it will be well placed to emerge at the other end of the crisis in a relatively strong financial position.

The company also believes that there will be a recovery in demand for its services as the crisis eases and elective surgeries return to normal. This is due to the high demand for Cochlear's products and the critical role they play in patients' lives.

Cochlear noted that the settlement of the placement is anticipated to occur on 30 March 2020. These shares are expected to be issued and start trading on the following day, 31 March.

Commenting on the successful capital raise, Cochlear Chairman Rick Holliday-Smith said: "We are grateful and delighted with the strong support for the Placement shown by our shareholders, with many having been shareholders for many years. We now have a fortified balance sheet and are well positioned to emerge from this global health pandemic in a strong competitive position."

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Phil Harpur owns shares of Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »